Drug development industry stakeholders recognise there is no one-size-fits-all approach to the long-standing challenge of patient recruitment and engagement.
Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh